Skip to main content
Erschienen in: Journal of Clinical Immunology 1/2015

01.01.2015 | Astute Clinician Report

Severe XLP Phenotype Caused by a Novel Intronic Mutation in the SH2D1A Gene

verfasst von: B. Tóth, B. Soltész, E. Gyimesi, G. Csorba, Á. Veres, Á. Lányi, G. Kovács, L. Maródi, M. Erdős

Erschienen in: Journal of Clinical Immunology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

We describe here a novel c.137 + 5G > A intronic mutation in the SH2D1A gene of the signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) in association with Epstein-Barr virus (EBV)-induced fatal infectious mononucleosis (FIM) in an 8-year-old male patient and his 3-year-old step brother. The mother and the maternal grandmother of the boys are healthy and heterozygous for this sequence variant. Genetic sequencing of blood-cell-derived cDNA in the younger patient revealed a 22 bp deletion in the SH2D1A cDNA. Immunoblot and flow cytometry analysis performed in this younger patient showed the lack of SAP protein expression in peripheral blood lymphocytes. These data suggest that the novel c.137 + 5G > A mutation results in loss of function of SAP protein and leads to typical X-linked lymphoproliferative disease phenotype. We propose that intron 1 and the c.137 + 5G may be the most frequent intronic hot spot for SH2D1A splicing mutation.
Literatur
1.
2.
Zurück zum Zitat Dupre L, Andolfi G, Tangye SG, Clementi R, Locatelli F, Arico M, et al. SAP controls the cytolytic activity of CD8 T cells against EBV-infected cells. Blood. 2005;105:4383–9.PubMedCrossRef Dupre L, Andolfi G, Tangye SG, Clementi R, Locatelli F, Arico M, et al. SAP controls the cytolytic activity of CD8 T cells against EBV-infected cells. Blood. 2005;105:4383–9.PubMedCrossRef
3.
Zurück zum Zitat Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet. 1975;7913:935–40.CrossRef Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet. 1975;7913:935–40.CrossRef
4.
Zurück zum Zitat Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38:471–8.PubMedCrossRef Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38:471–8.PubMedCrossRef
5.
Zurück zum Zitat Sümegi J, Seemayer TA, Huang D, Davis JR, Morra M, Gross TG, et al. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma. 2002;43:1189–201.PubMedCrossRef Sümegi J, Seemayer TA, Huang D, Davis JR, Morra M, Gross TG, et al. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma. 2002;43:1189–201.PubMedCrossRef
6.
Zurück zum Zitat Ma CS, Hare NJ, Nichols KE, Dupré L, Andolfi G, Roncarolo MG, et al. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. J Clin Invest. 2005;115:1049–59.PubMedCentralPubMedCrossRef Ma CS, Hare NJ, Nichols KE, Dupré L, Andolfi G, Roncarolo MG, et al. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. J Clin Invest. 2005;115:1049–59.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000;192:337–46.PubMedCentralPubMedCrossRef Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000;192:337–46.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Cuss AK, Avery DT, Cannons JL, Yu LJ, Nichols KE, Shaw PJ, et al. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol. 2006;176:1506–16.PubMedCrossRef Cuss AK, Avery DT, Cannons JL, Yu LJ, Nichols KE, Shaw PJ, et al. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol. 2006;176:1506–16.PubMedCrossRef
9.
Zurück zum Zitat Chaganti S, Ma CS, Bell AI, Croom-Carter D, Hislop AD, Tangye SG, et al. Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM + IgD + CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients. Blood. 2008;112:672–9.PubMedCrossRef Chaganti S, Ma CS, Bell AI, Croom-Carter D, Hislop AD, Tangye SG, et al. Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM + IgD + CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients. Blood. 2008;112:672–9.PubMedCrossRef
10.
Zurück zum Zitat Recher M, Fried AJ, Massaad MJ, Kim HY, Rizzini M, Frugoni F, et al. Intronic SH2D1A mutation with impaired SAP expression and agammaglobulinemia. Clin Immunol. 2012;146:84–9.PubMedCentralPubMedCrossRef Recher M, Fried AJ, Massaad MJ, Kim HY, Rizzini M, Frugoni F, et al. Intronic SH2D1A mutation with impaired SAP expression and agammaglobulinemia. Clin Immunol. 2012;146:84–9.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Latour S, Veillette A. Molecular and immunological basis of X-linked lymphoproliferative disease. Immunol Rev. 2003;192:212–24.PubMedCrossRef Latour S, Veillette A. Molecular and immunological basis of X-linked lymphoproliferative disease. Immunol Rev. 2003;192:212–24.PubMedCrossRef
12.
Zurück zum Zitat Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998;95:13765–70.PubMedCentralPubMedCrossRef Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998;95:13765–70.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117:1522–9.PubMedCrossRef Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117:1522–9.PubMedCrossRef
14.
Zurück zum Zitat Sumazaki R, Kanegane H, Osaki M, Fukushima T, Tsuchida M, Matsukura H, et al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus–associated illnesses. Blood. 2001;98:1268–70.PubMedCrossRef Sumazaki R, Kanegane H, Osaki M, Fukushima T, Tsuchida M, Matsukura H, et al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus–associated illnesses. Blood. 2001;98:1268–70.PubMedCrossRef
15.
Zurück zum Zitat Brandau O, Schuster V, Weiss M, Hellebrand H, Fink FM, Kreczy A, et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet. 1999;8:2407–13.PubMedCrossRef Brandau O, Schuster V, Weiss M, Hellebrand H, Fink FM, Kreczy A, et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet. 1999;8:2407–13.PubMedCrossRef
16.
Zurück zum Zitat Sümegi J, Huang D, Lányi A, Davis JD, Seemayer TA, Maeda A, et al. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118–25.PubMed Sümegi J, Huang D, Lányi A, Davis JD, Seemayer TA, Maeda A, et al. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118–25.PubMed
17.
Zurück zum Zitat Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nat. 1998;395:462–9.CrossRef Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nat. 1998;395:462–9.CrossRef
18.
Zurück zum Zitat Tabata Y, Villanueva J, Lee SM, Zhang K, Kanegane H, Miyawaki T, et al. Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood. 2005;105:3066–71.PubMedCrossRef Tabata Y, Villanueva J, Lee SM, Zhang K, Kanegane H, Miyawaki T, et al. Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood. 2005;105:3066–71.PubMedCrossRef
19.
Zurück zum Zitat Debeljak M, Podkrajsek KT, Aplenc R, Jazbec J. X-linked lymphoproliferative disease with a novel SH2D1A gene mutation. Pediatr Blood Cancer. 2008;50:187.PubMedCrossRef Debeljak M, Podkrajsek KT, Aplenc R, Jazbec J. X-linked lymphoproliferative disease with a novel SH2D1A gene mutation. Pediatr Blood Cancer. 2008;50:187.PubMedCrossRef
20.
Zurück zum Zitat Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129–35.PubMedCrossRef Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129–35.PubMedCrossRef
21.
Zurück zum Zitat Yin L, Ferrand V, Lavoué MF, Hayoz D, Philippe N, Souillet G, et al. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Genet. 1999;105:501–5.PubMedCrossRef Yin L, Ferrand V, Lavoué MF, Hayoz D, Philippe N, Souillet G, et al. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Genet. 1999;105:501–5.PubMedCrossRef
22.
Zurück zum Zitat Erdős M, Uzvölgyi E, Nemes Z, Török O, Rákóczi E, Went-Sümegi N, et al. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat. 2005;25:506.PubMedCrossRef Erdős M, Uzvölgyi E, Nemes Z, Török O, Rákóczi E, Went-Sümegi N, et al. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat. 2005;25:506.PubMedCrossRef
23.
Zurück zum Zitat Nagy N, Cerboni C, Mattsson K, Maeda A, Gogolak P, Sümegi J, et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer. 2000;88:439–47.PubMedCrossRef Nagy N, Cerboni C, Mattsson K, Maeda A, Gogolak P, Sümegi J, et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer. 2000;88:439–47.PubMedCrossRef
24.
Zurück zum Zitat Soltész B, Tóth B, Shabashova N, Bondarenko A, Okada S, Cypowyj S, et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet. 2013;50:567–78.PubMedCentralPubMedCrossRef Soltész B, Tóth B, Shabashova N, Bondarenko A, Okada S, Cypowyj S, et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet. 2013;50:567–78.PubMedCentralPubMedCrossRef
Metadaten
Titel
Severe XLP Phenotype Caused by a Novel Intronic Mutation in the SH2D1A Gene
verfasst von
B. Tóth
B. Soltész
E. Gyimesi
G. Csorba
Á. Veres
Á. Lányi
G. Kovács
L. Maródi
M. Erdős
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 1/2015
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-014-0117-1

Weitere Artikel der Ausgabe 1/2015

Journal of Clinical Immunology 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.